Literature DB >> 23607592

HCV treatment--no more room for interferonologists?

Joost P H Drenth.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23607592     DOI： 10.1056/NEJMe1303818

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  14 in total

Review 1.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

2.  International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.

Authors:  Jessica L Petrick; Megan Braunlin; Mathieu Laversanne; Patricia C Valery; Freddie Bray; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2016-06-28       Impact factor: 7.396

3.  Sofosbuvir.

Authors:  Dennis J Cada; Jasen Cong; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-05

4.  Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

Authors:  A Blythe Ryerson; Christie R Eheman; Sean F Altekruse; John W Ward; Ahmedin Jemal; Recinda L Sherman; S Jane Henley; Deborah Holtzman; Andrew Lake; Anne-Michelle Noone; Robert N Anderson; Jiemin Ma; Kathleen N Ly; Kathleen A Cronin; Lynne Penberthy; Betsy A Kohler
Journal:  Cancer       Date:  2016-03-09       Impact factor: 6.860

Review 5.  Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.

Authors:  Jagpreet Chhatwal; Tianhua He; Maria A Lopez-Olivo
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

6.  The changing burden of hepatitis C virus infection in the United States: model-based predictions.

Authors:  Mina Kabiri; Alison B Jazwinski; Mark S Roberts; Andrew J Schaefer; Jagpreet Chhatwal
Journal:  Ann Intern Med       Date:  2014-08-05       Impact factor: 25.391

7.  Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.

Authors:  Jun Hou; Gertine van Oord; Zwier M A Groothuismink; Mark A A Claassen; Kim Kreefft; Fatiha Zaaraoui-Boutahar; Wilfred F J van IJcken; Albert D M E Osterhaus; Harry L A Janssen; Arno C Andeweg; Robert J de Knegt; Andre Boonstra
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

Review 8.  Diagnostics and treatment of cryoglobulinaemia: it takes two to tango.

Authors:  Jan Damoiseaux; Jan Willem Cohen Tervaert
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

9.  Incorporating patient-reported outcomes into hepatitis C virus treatment studies.

Authors:  Donna M Evon
Journal:  Clin Gastroenterol Hepatol       Date:  2014-02-15       Impact factor: 11.382

10.  Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.

Authors:  Jessica L Petrick; Scott P Kelly; Sean F Altekruse; Katherine A McGlynn; Philip S Rosenberg
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.